SHANGHAI, Nov. 12, 2020 /PRNewswire/-- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare
services company offering patient management, online healthcare
information, professional training and educational services, today
announced that the Company and Takeda Pharmaceutical Company
Limited ("Takeda") agreed to expand their current scope of
cooperation which now covers five of Takeda's subsidiaries in
China including the new addition
of Baishen Biotechnology (Shanghai) Co., Ltd. Pursuant to the amended
service agreement by and between Zhongchao and Takeda, Zhongchao
shall continue to serve as Takeda's vendor and partner in
China, providing a broad range of
services in medical editing, document collation, and medical
training and education to Takeda.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "With over 50,000
employees and over $30 billion in
revenues (for the fiscal year ended March
31, 2020), Takeda is a global biopharmaceutical leader and a
Fortune Global 500 company. We are proud that we have been a vendor
and partner in China for various
medical training and education and brand building programs
sponsored by Takeda since 2018. Takeda has established itself as a
values-based, R&D-driven biopharma with strong presence in the
Chinese market and recently announced that it plans to bring at
least fifteen new drugs or indications into the Chinese market over
the next 5 years – widely regarded as one of the most aggressive
expansion plans in China by major
pharmaceutical companies. With the renewal of the contract by
Takeda with broadened scope of cooperation, we believe this
represents a significant opportunity for us to further grow our
business in years to come."
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
(TSE:4502/NYSE:TAK)("Takeda") is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in
Japan, committed to bringing
Better Health and a Brighter Future to patients by translating
science into highly-innovative medicines. Takeda focuses its
R&D efforts on four therapeutic areas: Oncology, Rare Diseases,
Neuroscience, and Gastroenterology (GI). Takeda also makes targeted
R&D investments in Plasma-Derived Therapies and Vaccines.
Takeda is focusing on developing highly innovative medicines that
contribute to making a difference in people's lives by advancing
the frontier of new treatment options and leveraging our enhanced
collaborative R&D engine and capabilities to create a robust,
modality-diverse pipeline. Takeda is committed to improving quality
of life for patients and to working with its partners in health
care in approximately 80 countries. More information can be found
at https://www.takeda.com.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online
provider of healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. The Company also offers patient
management services under its "Zhongxun" platform
(www.zhongxun.online). More information about the Company can be
found at its investor relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of
future performance and involve risks and uncertainties that may
cause the actual results to differ materially from the Company's
expectations discussed in the forward-looking statements. These
statements are subject to uncertainties and risks including, but
not limited to, the following: the Company's goals and
strategies; the Company's future business development; product and
service demand and acceptance; changes in technology; economic
conditions; the growth of the professional training and educational
services market in China and the
other international markets the Company plans to serve; reputation
and brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these
forward–looking statements to reflect events or
circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations:
Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:http://www.prnewswire.com/news-releases/zhongchao-inc-and-takeda-pharmaceutical-expand-scope-of-cooperation-in-china-301171065.html
SOURCE Zhongchao Inc.
